Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

age clinical studies," said Mr. Swisher.

Actions taken today will allow the company to direct most of its resources into the late-stage development of voreloxin. Sunesis expects this realignment of personnel and programs to reduce annual operating expenses by more than $15 million, thus enabling increased investment into such development. Current burn rate guidance for the second half of 2008 is in the range of $12-15 million, including payment of severance and other restructuring charges.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication- dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Maine , Dec. 22, 2014  Mark ... analysis brief providing a summary of the 2015 ... plan enrollment trends.  According to ... for Planning and Evaluation, Department of Health and ... were enrolled in individual medical plans through the ...
(Date:12/22/2014)... TAIPEI , Dec. 22, 2014 ... received Notice of Allowance for AC-201, TWi Biotechnology,s ... Office in China for ... or its pharmaceutically acceptable salts, active metabolite for ... covers the methods of treatment using AC-201 for ...
(Date:12/19/2014)... , Dec. 19, 2014 You,re visiting the ... and cleaning when he or she says you need ... heard before, you may have several questions and feel ... relieved to know it,s nothing to worry about. The ... questions and alleviate any anxiety the public may have ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Root Canals Have Become More Routine 2
... pharmaceutical products - particularly those that are first-in-class, socially ... not only external disease state communication but also internal ... a product for a new or relatively unknown condition ... the new disease before introducing a new product to ...
... Company (NYSE: LLY ) today announced that the ... a prior ruling by the U.S. District Court for the ... the company,s method-of-use patent on Strattera® (atomoxetine). In the case ... et al, the court ruled in favor of Lilly, ...
Cached Medicine Technology:Building Support for a New Product Through Effective Internal Disease State Communication 2U.S. Court of Appeals Affirms Validity of Lilly's Strattera Patent 2
(Date:12/22/2014)... Pasadena sleep apnea dentist, ... apnea. Drowsy drivers are 15 times more likely to ... and some experts believe that sleep-deprived drivers may be ... Unfortunately, millions of Americans may be sleep-deprived without even ... Medicine, about 18 million Americans have sleep apnea, but ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... Ill. (PRWEB) December 21, 2014 ... recommendations for chest computed tomography (CT) to evaluate ... relevant findings, including cancer, according to a new ... , Researchers said the findings show that radiologist ... represent valuable contributions to patient care. , RAIs, ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 In ... is segmented by power source, product, and application. ... electric-powered, battery-powered, and pneumatic instruments. By product, the ... and accessories segments. The handpieces market is further ... devices, suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, ...
(Date:12/21/2014)... Beverly Hills, Ca (PRWEB) December 21, 2014 ... Dr. Khanna was a guest at the Aspen Helicopters ... for kids and a Santa with sleigh, flown by ... the helicopter appeared invisible; only Santa with sleigh was ... both during day and night. Dr.Khanna has helped many ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Faced with a barrage of pressing issues, the ... agenda. The timing bodes well for change, according ... University Center for Health Policy and Professionalism, associate professor ... a pediatrician at Riley Hospital for Children. , "If ...
... Feb. 6 Turner Construction Company, the nation,s leading ... Northern Inyo Hospital to proceed with the $42 million ... for Phase Two will start in March 2009 with ... of a new central plant, emergency rooms, ICU, CCU, ...
... Colo., Feb. 6 Baxa Corporation, an Englewood Colorado-based medical ... of the Top 50 Family-Owned Companies in Colorado. Qualifying ... be controlled by a single family, and controlling family members ... has to have been involved in the company for at ...
... Medical Group Inc.,(OTC Bulletin Board: WMDG; "Winner Medical"), ... and wound care products) in China, today,announced that ... first quarter,ended December 31, 2008 on Friday, February ... The earnings release will be available on the ...
... (Nasdaq: EVVV ) will release its 2008 fourth ... 2009 on Tuesday, Febuary 24, 2009, before regular market trading ... same day at 7:30 a.m. Central Time (8:30 a.m. Eastern ... full-year operating results and future outlook, followed by a question ...
... ... Brookfield, Wisconsin (PRWEB) February 6, 2009 -- Watching your weight? ... International Foundation of Employee Benefits Plans found that of those ... loss program., , ,When asked their primary reason for offering a ...
Cached Medicine News:Health News:Prioritizing health-care reform components 2Health News:Turner to Manage Construction of $42 Million Expansion of Northern Inyo Hospital in Bishop, Calif. 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 2Health News:Baxa Corporation Ranks Seventh in ColoradoBiz Magazine's Top 50 Family-Owned Companies 3Health News:Winner Medical Schedules 2008/2009 First Quarter Earnings Release on Friday, February 13, 2009 2Health News:ev3 Inc. to Report 2008 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 24, 2009 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 2Health News:Employee Weight Loss Programs Offered By Half of Employers Who Provide Wellness Programs 3
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: